Markers of response to CDK4 & 6 inhibition from neoMONARCH: A phase II neoadjuvant study of abemaciclib in postmenopausal women with hormone receptor positive, HER2 negative breast cancer

被引：1
|
作者：
Hurvitz, S.
Martin, M.
Wijayawardana, S.
Brahmachary, M.
Ebert, Pj
Young, S.
Jansen, V.
Slamon, D.
机构：
[1] Univ Calif Los Angeles, Los Angeles, CA USA
[2] Hosp Gen Univ Gregorio Maranon, Madrid, Spain
[3] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-P3-10-08
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-10-08
引用
收藏
页数：2
相关论文
共 50 条
  • [31] The association of hormone receptor expression level and clinical efficacy of CDK4/6 inhibitor in hormone receptor-positive, HER2-negative metastatic breast cancer
    Bao, Kelvin K. H.
    Wong, Carol H. Y.
    Yung, Jackie
    Tam, Venus
    Cheung, Ka Man
    Chan, Jeffrey C. H.
    Yiu, Harry H. Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [32] The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer
    Grinshpun, Albert
    Tolaney, Sara M. M.
    Burstein, Harold J. J.
    Jeselsohn, Rinath
    Mayer, Erica L. L.
    NPJ BREAST CANCER, 2023, 9 (01)
  • [33] The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer
    Albert Grinshpun
    Sara M. Tolaney
    Harold J. Burstein
    Rinath Jeselsohn
    Erica L. Mayer
    npj Breast Cancer, 9
  • [34] Biomarkers of response to CDK4/6 inhibitor (CDK4/6i) in hormone receptor (HR) positive and HER2-positive breast cancer (BC) patient-derived xenografts (PDX)
    Palafox, Marta
    Herrera-Abreu, Maria Teresa
    Bellet, Meritxell
    Oliveira, Mafalda
    Bruna, Alejandra
    Rodriguez, Olga
    Guzman, Marta
    Grueso, Judit
    Vilaplana, Cristina
    Arribas, Joaquin
    di Tomaso, Emmanuelle
    Su, Faye
    Caldas, Carlos
    Turner, Nicholas C.
    Dienstmann, Rodrigo
    Baselga, Jose
    Scaltriti, Maurizio
    Cortes, Javier
    Saura, Cristina
    Serra, Violeta
    CANCER RESEARCH, 2018, 78 (13)
  • [35] A phase I trial of palbociclib and bosutinib with fulvestrant in patients with metastatic hormone receptor positive and HER2 negative (HR+ HER2-) breast cancer refractory to an aromatase inhibitor and a CDK4/6 inhibitor
    Roy, Tina
    Barrows, Elizabeth
    Mainor, Candace
    Collins, Julie
    Lynce, Filipa
    Isaacs, Claudine
    Pohlmann, Paula R.
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2023, 33
  • [36] Evaluate the impact of HER2 status on the response to CDK4/6 inhibitors in advanced breast cancer
    Goncalves, M. Veloso
    Teixeira, C.
    Valente, A. C.
    Reis, J.
    Teixeira, N.
    Sousa, I.
    Almeida, D.
    Augusto, I.
    Barbosa, M.
    Meireles, S.
    EUROPEAN JOURNAL OF CANCER, 2024, 200 : 55 - 55
  • [37] Validation of Magee equation in predicting response to neoadjuvant chemotherapy in breast cancer patients with hormone receptor positive and HER2 negative
    Saigosoom, N.
    O-charoenrat, P.
    Udompunturak, S.
    Sanguanraksa, D.
    BREAST, 2019, 44 : S73 - S73
  • [38] Application of CDK4/6 Inhibitors in Premenopausal Women with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: a Real-World Experience
    Kurbacher, Christian M.
    Fischer, Lotta Ada
    Heinrich, Georg
    Herz, Susanne
    Schott, Alexander
    Kurbacher, A. Tabea
    Kurbacher, Jutta Anna
    Rudlowski, Christian
    Warm, Mathias R.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 19 - 19
  • [39] Abemaciclib, an inhibitor of CDK4 and CDK6, combined with endocrine and HER2-targeted therapies for women with metastatic breast cancer
    Goetz, M. P.
    Beeram, M.
    Beck, T.
    Conlin, A. K.
    Dees, E. C.
    Dickler, M. N.
    Helsten, T. L.
    Conkling, P. R.
    Edenfield, W. J.
    Richards, D. A.
    Turner, P. K.
    Cai, N.
    Chan, E. M.
    Pant, S.
    Becerra, C. H.
    Kalinsky, K.
    Puhalla, S. L.
    Rexer, B. N.
    Burris, H. A.
    Tolaney, S. M.
    CANCER RESEARCH, 2016, 76
  • [40] CDK4/6 inhibitor dalpiciclib combined with letrozole as neoadjuvant therapy in postmenopausal patients with hormone receptor- positive, HER2-negative stage II-III breast cancer: a single-arm exploratory trial
    Zhang, Lina
    Yang, Chao
    Ma, Jie
    Li, Yuntao
    Luo, Ruizhen
    Han, Jianjun
    Wang, Xiaochun
    Zhang, Zhisheng
    Ma, Li
    Cai, Haifeng
    Kong, Xiangshun
    Wang, Zunyi
    Zhou, Xinping
    Liu, Yueping
    Shi, JiaJie
    Zhang, Yanshou
    Wang, Meiqi
    Wang, Jiaxing
    Geng, Cuizhi
    CANCER RESEARCH, 2024, 84 (09)
12345